Description
SR9009 (Stenabolic) Research Chemical
SR9009 (Stenabolic) is a Rev-erb α/β agonist developed at Scripps Research Institute by Thomas Burris. Despite being commonly sold alongside SARMs, SR9009 is mechanistically distinct — it activates Rev-erb nuclear receptors, which are master regulators of circadian clock gene expression and metabolic gene programs (lipid and glucose metabolism, mitochondrial biogenesis).
Research Applications
- Circadian biology: Rev-erb agonism and clock gene regulation (Bmal1, Clock suppression)
- Metabolic research: fat oxidation gene expression, lipid metabolism
- Atherosclerosis models — Rev-erb and macrophage inflammatory biology
- Exercise mimetic studies — comparison with SLU-PP-332 (ERR) and AICAR (AMPK)
- Inflammation models — Rev-erb and NF-κB crosstalk
Product Specifications
- Purity: ≥98% HPLC confirmed
- Identity: Mass spectrometry (MW: 437.94)
- CoA: Third-party laboratory, every batch
- Form: Lyophilized powder, sealed glass vial
For Research Use Only (RUO). Not for human consumption.
